FDA Brief

Warning letters Drugs

FDA warning letter to

Higley Industries, Inc.

High riskIssued Feb 22, 2024Posted Mar 26, 2024Division of Pharmaceutical Quality Operations III

FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

What happened

FDA inspected Higley Industries' drug manufacturing facility in Dyersville, Iowa, from September 19 to September 21, 2023. FDA found the firm did not adequately test incoming components such as ethanol for methanol and glycerin for diethylene glycol or ethylene glycol, and relied on supplier certificates without establishing their reliability. FDA also found missing process validation for hand sanitizer and inadequate quality unit oversight.

What FDA found

  1. Failed to adequately test incoming ethanol for methanol and glycerin for diethylene glycol or ethylene glycol before use, and failed to show that water used as a component met the United States Pharmacopeia water standard.

    21 CFR 211.84(d)(1) and (2)
  2. Failed to validate the manufacturing process and qualify equipment for the hand sanitizer; the firm said any filling line could be used but could not provide process validation documentation.

    21 CFR 211.100(a)
  3. The quality unit did not ensure adequate evaluation of product quality before batch release, and the Quality Manual gave the Shipping Clerk final authority to review and approve drug product for release.

    21 CFR 211.22(a)
  4. Batch production and control records did not document each significant manufacturing step for each drug product batch.

    21 CFR 211.188(b)
  5. Failed to establish adequate written procedures for test methods and sampling plans, an adequate ongoing stability program, and periodic product reviews.

    21 CFR 211.160(b), 211.166(a), 211.180(e)

What FDA wants

FDA asks the company to respond in writing within 15 working days describing what it has done to address the violations and prevent recurrence, and to state reasons and a completion schedule if corrective actions cannot be finished in that time.

Who should pay attention

  • brands that buy OTC drugs or hand sanitizer from this contract manufacturer
  • suppliers and distributors of ethanol or glycerin used in drugs
  • quality teams at other OTC drug manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk